h.dumitru99/100
Costed them per mg against three other suppliers on the same IGF-1 LR3 1 mg spec. Competitive on price and clearly ahead on documentation.
Homopeptide — Hunan Aslsen Technology Co., Ltd.
Changsha, CN. The index holds 575 assay reports across 93 batches and 36 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where Homopeptide sells
Hunan Aslsen Technology Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit Homopeptide at homopeptide.net →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Hunan Aslsen Technology Co., Ltd.
- Short code in this index
- Homopeptide
- Also known as
- Homopeptide · Homopeptide Bio · Aslsen
- Domain
- homopeptide.net →
- City
- Changsha
- Region
- Hunan
- Country
- CN
- Established
- not stated
- First record in index
- 28 Jan 2024
- Most recent record
- 04 Oct 2026
Block 1b
Dispatch and warehouses
Where the supplier holds regional stock. Material assayed by the index is dispatched from these locations, not from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
99.34%
n=575
Interquartile range
0.81pp
n=575
10th percentile
98.47%
n=575
Pass rate vs index spec
98.4%
n=575
Median recovery vs claim
98.5%
n=345
Median water
5.10%
n=575
Median |mass error|
2.5ppm
n=491
Records carrying a flag
80.3%
n=575
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.86pp
n=74
Index median spread
0.95pp
n=20
Lots tested 3+ times
74
n=93
Across the 74 Homopeptide lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.86 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.29pp
n=93
Index median divergence
+0.31pp
n=20
Divergences in the supplier's favour
83%
n=93
Divergences beyond 1 pp
2%
n=93
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.95%
n=71
Supplier-supplied median
99.43%
n=467
Supplier-supplied share of records
81.2%
n=575
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of Homopeptide batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
85/100
n=93
Index median score
79/100
n=20
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 75% | 25 points | |
| Peptide content stated | 63% | 20 points | |
| Endotoxin stated | 33% | 15 points | |
| Named impurities rather than a total | 57% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Semaglutide | Incretin | 121 | 99.20 | 98.87 | +0.33 | 97.0 | 100 |
| Retatrutide | Incretin | 72 | 98.53 | 98.41 | +0.12 | 96.5 | 100 |
| Melanotan II | Melanocortin-receptor | 37 | 99.26 | 99.24 | +0.02 | 98.5 | 95 |
| GHRP-6 | Growth-hormone | 33 | 99.93 | 99.65 | +0.28 | 99.0 | 100 |
| Tirzepatide | Incretin | 28 | 98.67 | 98.44 | +0.23 | 97.0 | 100 |
| TB-500 | Tissue-repair | 26 | 99.38 | 99.47 | -0.09 | 98.5 | 100 |
| BPC-157 | Tissue-repair | 25 | 99.39 | 99.15 | +0.24 | 98.0 | 100 |
| Semax | Neuroactive | 23 | 99.69 | 99.17 | +0.52 | 98.5 | 100 |
| SS-31 (Elamipretide) | Metabolic | 22 | 99.64 | 99.42 | +0.22 | 98.5 | 95 |
| N-Acetyl Semax Amide | Neuroactive | 18 | 99.27 | 99.26 | +0.00 | 98.5 | 100 |
| KPV | Tissue-repair | 13 | 99.28 | 99.21 | +0.07 | 99.0 | 62 |
| Ipamorelin | Growth-hormone | 12 | 99.53 | 99.48 | +0.05 | 99.0 | 100 |
| LL-37 | Tissue-repair | 12 | 99.30 | 98.61 | +0.69 | 96.5 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 12 | 99.52 | 99.31 | +0.20 | 98.5 | 100 |
| GHRP-2 | Growth-hormone | 11 | 99.59 | 99.22 | +0.37 | 99.0 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 11 | 99.83 | 99.37 | +0.46 | 98.5 | 100 |
| Humanin (HNG) | Metabolic | 11 | 99.71 | 99.47 | +0.24 | 97.5 | 100 |
| L-Carnosine | Short | 10 | 99.47 | 99.07 | +0.41 | 99.0 | 90 |
| Survodutide | Incretin | 9 | 99.57 | 98.69 | +0.88 | 96.5 | 100 |
| SLU-PP-332 | Non-peptide | 8 | 99.50 | 98.69 | +0.82 | 98.0 | 100 |
| Liraglutide | Incretin | 8 | 99.93 | 99.02 | +0.92 | 97.5 | 100 |
| Leuprolide | Hypothalamic | 8 | 99.57 | 99.01 | +0.56 | 98.5 | 100 |
| L-Glutathione (reduced) | Short | 8 | 99.19 | 99.00 | +0.19 | 98.5 | 100 |
| CJC-1295 (no DAC) | Growth-hormone | 7 n=7 | 99.33 | 98.61 | +0.72 | 98.0 | 100 |
| Afamelanotide | Melanocortin-receptor | 6 n=6 | 99.12 | 99.28 | -0.16 | 98.0 | 100 |
| GHK-Cu | Tissue-repair | 6 n=6 | 99.00 | 98.54 | +0.46 | 97.0 | 100 |
| Hexarelin | Growth-hormone | 3 n=3 | 99.93 | 98.72 | +1.21 | 99.0 | 100 |
| ARA-290 | Tissue-repair | 3 n=3 | 99.74 | 99.45 | +0.29 | 98.0 | 100 |
| PEG-MGF | Growth-hormone | 3 n=3 | 98.47 | 97.92 | +0.55 | 92.0 | 100 |
| Epitalon | Short | 2 n=2 | n<3 | 98.63 | — | 99.0 | 100 |
| Oxytocin | Hypothalamic | 2 n=2 | n<3 | 99.57 | — | 98.5 | 100 |
| IGF-1 LR3 | Growth-hormone | 1 n=1 | n<3 | 97.75 | — | 95.0 | 100 |
| Glucagon | Incretin | 1 n=1 | n<3 | 98.78 | — | 98.0 | 100 |
| Dihexa | Neuroactive | 1 n=1 | n<3 | 99.84 | — | 98.5 | 100 |
| Selank | Neuroactive | 1 n=1 | n<3 | 99.13 | — | 99.0 | 100 |
| MOTS-c | Metabolic | 1 n=1 | n<3 | 99.18 | — | 98.0 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 2 | 17 | 99.23 | 98.61–99.93 | 3 |
| 2024-Q2 | 6 | 27 | 99.32 | 97.14–99.93 | 24 |
| 2024-Q3 | 9 | 42 | 98.66 | 97.41–99.93 | 34 |
| 2024-Q4 | 4 | 30 | 99.69 | 98.81–99.93 | 19 |
| 2025-Q1 | 9 | 67 | 99.58 | 98.58–99.93 | 48 |
| 2025-Q2 | 8 | 60 | 99.61 | 97.69–99.93 | 50 |
| 2025-Q3 | 7 | 52 | 98.85 | 97.76–99.93 | 51 |
| 2025-Q4 | 17 | 125 | 99.24 | 97.66–99.93 | 117 |
| 2026-Q1 | 13 | 66 | 99.41 | 98.43–99.93 | 55 |
| 2026-Q2 | 10 | 37 | 99.57 | 98.07–99.93 | 23 |
| 2026-Q3 | 8 | 52 | 99.44 | 98.34–99.93 | 38 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 283 | 99.40 | +0.00 | 99.40 |
| PeptideMeter | 91 | 99.23 | -0.05 | 99.28 |
| Medutest | 70 | 99.41 | +0.08 | 99.33 |
| VendorInvestigate | 53 | 98.87 | -0.11 | 98.98 |
| Nordanalyt | 41 | 99.44 | +0.02 | 99.42 |
| Kestrel | 37 | 99.80 | +0.24 | 99.56 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
99.0/ 100557 ratings across the index network
j.boateng99/100
Vial labels printed rather than handwritten, lot and date legible, cap seal intact on every unit.
h.ogunleye99/100
Arrived on day 3 against a quoted 4. Customs paperwork was right first time, which is why it moved that fast.
ha.frisk96/100
Straightforward order, arrived as described, documentation adequate and complete. Nothing to add, which is the point.
f.duarte99/100
Moved here after two bad lots elsewhere. 3 orders in and the Medutest numbers have been flat every single time.
k.nyberg99/100
Support answered on a Sunday, correctly, with the batch record attached. That is well beyond what I expected.
b.kaufmann99/100
Weighed 9 vials from the LL-37 5 mg order against label. Every one inside 2% of stated mass. Fill consistency is harder than purity and they have it.
l.petrescu99/100
No customs paperwork, no import wait — it came from their stock in Australia and arrived day 5.
ra.vermeulen96/100
Fair pricing for the documentation standard, and delivery landed on day 4 as quoted.
w.perrin99/100
Vials wrapped individually, foam cut to fit, nothing loose in the box. Packing that has clearly been thought about.
l.boateng99/100
First order, deliberately small, epithalon 10 mg only. Documentation, transit and a Janoshik result at 99.4% all checked out, so the next one will not be small.
co.grimaldi99/100
Documentation is better than the two suppliers I used before, and the catalogue covers everything I actually order.
p.yildiz99/100
The ipamorelin 5 mg arrived on day 2 with the cold pack intact and the seal unbroken. Straightforward, exactly as described.
b.halvorsen99/100
Peptide content reported at 97.7% alongside the purity figure, so I could convert straight to a working mass.
s.hovland96/100
Shipped from their warehouse in the United States, arrived day 2, documentation complete.
ca.ramos96/100
Documentation is complete and the numbers are steady. A dependable choice for routine work.
tu.kaufmann99/100
Ordered on a Monday from their warehouse in Germany and it was here by day 4. That is the whole case for regional stock.
s.ndiaye96/100
Reliable on the general catalogue lines. Purity figures cluster tightly and the certificates match the lots.
ka.castellanos99/100
Their raw material tested 99.8% against a reseller vial of nominally the same compound at 99.3%. Going direct is the whole argument.
a.espinoza96/100
Good communication throughout, accurate lead time, and the parcel arrived on day 4.
l.ndiaye99/100
Submitted the ipamorelin 5 mg to Medutest blind, without telling them the source. 98.5% against a stated 98.1%. The number holds up when nobody knows whose vial it is.
e.salgado99/100
Same lot documentation as the factory ships, but out of their warehouse in Australia, so it landed on day 4.
a.salgado96/100
Domestic dispatch from their stock in Canada. Straightforward, day 3, exactly as quoted.
p.roos99/100
Shipped with a stated storage recommendation and a shelf-life figure tied to it, without my asking.
r.solberg99/100
Regional stock makes the difference — dispatched within Australia, day 3, cold pack still hard on arrival.
e.demir96/100
Solid on the glutathione 600 mg. Purity where it should be, transit 3 days, paperwork in order.
Block 12
Most recent records
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042181 | Ipamorelin | HOMO-2608-A9045 | Janoshik | 2026-Q3 | 99.78 | 4.79 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042172 | Semaglutide | HOMO-2604-X8921 | Janoshik | 2026-Q3 | 99.64 | 5.16 | 91.9 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042278 | SLU-PP-332 | HOMO-2602-Y2822 | Kestrel | 2026-Q3 | 99.71 | 4.42 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042180 | Ipamorelin | HOMO-2608-A9045 | Janoshik | 2026-Q3 | 99.39 | 4.74 | 105.5 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042184 | Ipamorelin | HOMO-2608-A9045 | Kestrel | 2026-Q3 | 99.27 | 4.79 | 103.2 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042274 | SLU-PP-332 | HOMO-2602-Y2822 | VendorInvestigate | 2026-Q3 | 98.71 | 4.72 | — | Laboratory-retained | 0 | PASS |
| AX-2026-042183 | Ipamorelin | HOMO-2608-A9045 | VendorInvestigate | 2026-Q3 | 99.38 | 4.97 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042194 | Retatrutide | HOMO-2605-V9833 | PeptideMeter | 2026-Q3 | 98.90 | 4.07 | 98.8 | Supplier-supplied | 3 | MARGINAL |
| AX-2026-042191 | Ipamorelin | HOMO-2608-A9045 | Medutest | 2026-Q3 | 99.67 | 5.00 | 104.6 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042216 | LL-37 | HOMO-2602-G1280 | Kestrel | 2026-Q3 | 98.97 | 5.30 | 93.4 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042195 | Retatrutide | HOMO-2605-V9833 | Kestrel | 2026-Q3 | 98.99 | 4.02 | 107.2 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042185 | Ipamorelin | HOMO-2608-A9045 | Nordanalyt | 2026-Q3 | 99.26 | 4.63 | 95.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042167 | Semaglutide | HOMO-2604-X8921 | Janoshik | 2026-Q3 | 99.57 | 5.06 | 104.9 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042276 | SLU-PP-332 | HOMO-2602-Y2822 | Janoshik | 2026-Q3 | 99.58 | 4.95 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042279 | SLU-PP-332 | HOMO-2602-Y2822 | Janoshik | 2026-Q3 | 99.27 | 4.62 | 90.9 | Supplier-supplied | 0 | PASS |
| AX-2026-042215 | LL-37 | HOMO-2602-G1280 | PeptideMeter | 2026-Q3 | 99.83 | 5.36 | 89.9 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042178 | Semaglutide | HOMO-2604-X8921 | Janoshik | 2026-Q3 | 99.38 | 5.21 | 101.3 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042217 | LL-37 | HOMO-2602-G1280 | Janoshik | 2026-Q3 | 99.43 | 5.69 | 105.8 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042238 | IGF-1 LR3 | HOMO-2607-P1246 | PeptideMeter | 2026-Q3 | 98.34 | 6.38 | 95.0 | Laboratory-retained | 0 | PASS |
| AX-2026-042177 | Semaglutide | HOMO-2604-X8921 | Janoshik | 2026-Q3 | 99.49 | 4.94 | 104.3 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042189 | Ipamorelin | HOMO-2608-A9045 | Janoshik | 2026-Q3 | 99.63 | 5.00 | 102.4 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042186 | Ipamorelin | HOMO-2608-A9045 | Medutest | 2026-Q3 | 99.44 | 4.68 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042169 | Semaglutide | HOMO-2604-X8921 | Kestrel | 2026-Q3 | 99.56 | 4.69 | 101.5 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042280 | SLU-PP-332 | HOMO-2602-Y2822 | VendorInvestigate | 2026-Q3 | 99.16 | 5.05 | 105.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042273 | SLU-PP-332 | HOMO-2602-Y2822 | PeptideMeter | 2026-Q3 | 99.81 | 4.60 | 88.9 | Supplier-supplied | 2 | MARGINAL |